[关键词]
[摘要]
目前传统的心脏毒性评价指标乳酸脱氢酶(LDH)、门冬氨酸氨基转移酶(AST)、肌酸激酶(CK)以及肌酸激酶同工酶(CK-MB)等在早期毒性评价中均有局限性,因此急需灵敏度高、特异性强的生物标记物进行早期心脏毒性评价.随着基因组学、转录组学、蛋白质组学和代谢组学的不断发展,评价药物早期心脏毒性生物标记物的研究也有了新的进展.对基因类、蛋白类以及代谢小分子类心脏毒性生物标记物的研究进展加以综述,为进一步对早期心脏毒性生物标记物的研究提供更好的理论支持.
[Key word]
[Abstract]
The traditional evaluation indexes of cardiotoxicity [lactate dehydrogenase (LDH), aspartate transaminase (AST), creatine kinase (CK), and creatine kinase isoenzymes (CK-MB)] in early toxicity evaluation has limitations, so it is urgent to need high sensitivity, specificity of biomarkers for toxicity evaluation in the early stage of cardiotoxicity. With the development of genomics, transcriptomics, proteomics, and metabolomics, the continuous development of the biomarkers for early prediction of cardiotoxicity also get new progress. This study was reviewed from the progress of the biomarkers for early prediction of cardiotoxicity in gene, protein and small molecule metabolism, in order to provide better theoretical support for the study of the biomarkers for early prediction of cardiotoxicity.
[中图分类号]
[基金项目]
国家自然科学基金资助项目(81273998)